Advanced Filters
noise
Found 63,122 clinical trials
P Pietro Invernizzi, MD

National Database on Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is a rare, autoimmune, cholestatic liver disease. No data about the disease epidemiology exist in Italy. Therefore this study aims to develop a national PBC patient database linked to a biological sample storage.

18 years of age All Phase N/A
Z Zulaika Grille Cancela

Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

Demonstrate the impact of the Molecular Microscope Diagnostic System as the standard of care for heart transplant patients.

18 years of age All Phase N/A
D DAVID MEYA, PhD

Platform Trial For Cryptococcal Meningitis

Cryptococcal meningitis is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. Even with antifungal therapy, mortality rates remain high, especially in low and middle income countries where the ongoing HIV/AIDS pandemic increases the risk of cryptococcosis among persons living with HIV …

18 years of age All Phase 2/3
Q Qin Liu, MD

Quantitative Consciousness Index Monitoring (qNOX) of Sedation During Endoscopy

Nociception is the encoding and processing of noxious stimulation and is considered an objective indicator for monitoring pain. Currently, a new clinically-applied medical-engineering integrated monitoring device for noxious stimulation response has emerged. Its fundamental principle is based on the monitoring of electroencephalographic (EEG) activity, incorporating two monitoring parameters: the quantitative …

18 - 60 years of age All Phase N/A
S Study Director

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: JX10 improves functional outcomes as measured by the modified …

18 - 90 years of age All Phase 2/3
K Kazutaka Uchida, MD, PhD

Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma

COMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle meningeal artery embolization for chronic subdural hematoma.

18 years of age All Phase N/A
U US GSK Clinical Trials Call Center

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

18 - 70 years of age All Phase 2
L Lele Zhang, PhD

National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia

Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The objectives of this study are to …

years of age All Phase N/A
U US GSK Clinical Trials Call Center

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

40 - 80 years of age All Phase 3
D Dimitrios T Boumpas, Professor in Medicine

Does Belimumab Modify the Natural History of SLE? A Propensity Score-matched, Real-world Study

This will be a combined retrospective and prospective cohort study, that will evaluate the incidence of de novo Systemic Lupus Erythematosus major organ manifestations (defined as BILAG A flares) in patients receiving belimumab (Arm A) and compare it to 2 standard-of-care groups (SoC) (Arm B: patients on SoC; Arm C: …

18 years of age All Phase N/A

Simplify language using AI